Agustin Garcia
University of Southern California · Univrsity of Southern California · Cedars-Sinai Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Agustin Garcia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:28 UTC. Open this list on ClinicalTrials.gov
- N/ANCT01695057 · Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast CancerUniversity of Southern California · withdrawn · Stage II Breast Cancer, Stage IIIA Breast Cancer, Triple-negative Breast Cancer · principal investigator
- Ph1NCT01649258 · Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing ChemotherapyUniversity of Southern California · terminated · Breast Cancer, Nausea, Vomiting · principal investigator
- N/ANCT01292083 · Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By SurgeryUniversity of Southern California · withdrawn · Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer · principal investigator
- Ph2NCT01227408 · Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast CancerUniversity of Southern California · withdrawn · Breast Cancer · principal investigator
- Ph1NCT01170871 · Ixabepilone and Pemetrexed/Solid TumorsUniversity of Southern California · withdrawn · Advanced Solid Tumors · principal investigator
- Ph1NCT01155258 · Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsUniversity of Southern California · completed · Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer · principal investigator
- Ph2NCT00183794 · Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal CarcinomaUniversity of Southern California · completed · Ovarian Carcinoma, Peritoneal Neoplasms · principal investigator
- N/ANCT00126464 · Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the BreastCedars-Sinai Medical Center · unknown · Breast Cancer · study chair
- N/ANCT00114296 · Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast CancerCedars-Sinai Medical Center · unknown · Breast Cancer · study chair
- Ph2NCT00113373 · Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal CancerNational Cancer Institute (NCI) · completed · Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer · principal investigator
- Ph2NCT00002955 · Combination Chemotherapy in Treating Patients With Advanced Cancer of the PancreasUniversity of Southern California · completed · Pancreatic Cancer · study chair
- Ph2NCT00085332 · Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)Gynecologic Oncology Group · completed · Endometrial Cancer · study chair
- Ph1NCT00003773 · IM-862 in Treating Patients With Recurrent Ovarian CancerUniversity of Southern California · completed · Ovarian Cancer · study chair
- Ph2NCT00006812 · Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity CancerGynecologic Oncology Group · terminated · Ovarian Cancer, Primary Peritoneal Cavity Cancer · study chair
- Ph2NCT00072566 · Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal CancerNational Cancer Institute (NCI) · completed · Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer · principal investigator
- Ph2NCT00003449 · Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian CancerUniversity of Southern California · completed · Ovarian Cancer · study chair
- Ph2NCT00016926 · Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical CancerGynecologic Oncology Group · completed · Cervical Cancer · study chair
- Ph2NCT00041093 · Docetaxel in Treating Patients With Persistent or Recurrent Cervical CancerGynecologic Oncology Group · completed · Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma · principal investigator
- Ph2NCT00026091 · Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal CancerNational Cancer Institute (NCI) · completed · Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IV Ovarian Epithelial Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- PHASE I CLINICAL AND PHARMACOKINETIC TRIAL OF INTRAPERITONEAL IRINOTECANM01RR000043 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2004 to 2008 · $6,010 awarded in 2008Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Gynecologic Oncology GroupU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI Philip J. DiSaia · fiscal years 2008 to 2013Named on NCT00113373, NCT00041093
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2008 to 2026Named on NCT00072566
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:28 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.N Engl J Med · 2015400 citationsRCR 14.0
- ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.Clin Cancer Res · 2020209 citationsRCR 10.0
- The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors.Oncol Nurs Forum · 1998171 citationsRCR 6.1
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.J Clin Oncol · 2015153 citationsRCR 4.4
- A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.Breast Cancer Res Treat · 2012152 citationsRCR 4.0
- Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.Clin Cancer Res · 2017132 citationsRCR 4.1
- 83 citationsRCR 2.3
- Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.Breast Cancer Res Treat · 201553 citationsRCR 1.4
- Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.Lancet Oncol · 201352 citationsRCR 1.5
- Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.Breast Cancer Res Treat · 201348 citationsRCR 1.6